BR38, a new ultrasound blood pool agent

Investigative Radiology

Volumn 46, Issue 8, 2011, Pages 486-494

  Schneider, Michel ^a   Anantharam, Brijesh ^b   Arditi, Marcel ^a   Bokor, Daniela ^c   Broillet, Anne ^a   Bussat, Philippe ^a   Fouillet, Xavier ^a   Frinking, Peter ^a   Tardy, Isabelle ^a   Terrettaz, Jacques ^a   Senior, Roxy ^b,d   Tranquart, François ^a  

^a Bracco Suisse SA   (Switzerland)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c Bracco Imaging SpA   (Italy)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

BR38; liver imaging; myocardial perfusion imaging; phase I; safety; ultrasound contrast agent

Indexed keywords

BR 38; ECHO CONTRAST MEDIUM; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEART MUSCLE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; HYDROSTATIC PRESSURE; LABORATORY TEST; LIVER; MALE; MICROBUBBLE; NONHUMAN; NORMAL HUMAN; OSMOLALITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RABBIT; RAT; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SURFACE CHARGE; SWINE; VISCOSITY; VITAL SIGN;

EID: 79959787165     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318217b821     Document Type: Article

References (31)

1. Kasprzak JD, Ten Cate FJ. New ultrasound contrast agents for left ventricular and myocardial opacification. Herz. 1998;23:474-482. (Pubitemid 29006224)
2. Pochon S, Tardy I, Bussat P, et al. BR55: a lipopeptide-based VEGF-R2 targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol. 2010;45:89-95.
3. Pysz MA, Foygel K, Rosenberg J, et al. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology. 2010;256:519-527.
4. Anderson CR, Rychak JJ, Backer M, et al. scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invest Radiol. 2010;45:579-585.
5. Fischer T, Thomas A, Tardy I, et al. Vascular endothelial growth factor receptor-2-specific microbubbles for molecular ultrasound detection of prostate cancer in a rat model. Invest Radiol. 2010;45:675-684.
6. Guenther F, von zur Mulhen C, Ferrante EA, et al. An ultrasound contrast agent targeted to P-selectin detects activated platelets at supra-arterial shear flow conditions. Invest Radiol. 2010;45:586-591.
7. Hayat SA, Senior R. Myocardial contrast echocardiography in ST elevation myocardial infarction: ready for prime time? Eur Heart J. 2008;29:299-314. (Pubitemid 351197767)
8. Feinstein SB, Coll B, Staub D, et al. Contrast enhanced ultrasound imaging. J Nuclear Cardiol. 2010;17:106-115.
9. Schneider M, Arditi M, Barrau, et al. BR1: a new ultrasonographic contrast agent based on sulfur hexafluoride-filled microbubbles. Invest Radiol. 1995; 30:451-457.
10. Irwin S. Comprehensive observational assessment: 1a. A systematic, quantitative procedure for assessing the behavioural and physiologic state of the mouse. Psychopharmacologia (Berl). 1968;13:222-257.
11. Marmottant P, van der Meer S, Emmer M, et al. A model for large amplitude oscillations of coated bubbles accounting for buckling and rupture. J Acoust Soc Am. 2005;118:3499-3505. (Pubitemid 41820855)
12. Gorce JM, Arditi M, Schneider M. Influence of bubble size distribution on the echogenicity of ultrasound contrast agents-a study of SonoVue. Invest Radiol. 2000;35:661-671.
13. Sontum PC. Physicochemical characteristics of Sonazoid, a new ultrasound contrast agent for ultrasound imaging. Ultrasound Med Biol. 2008;34:824-833. (Pubitemid 351608046)
14. Fisher NG, Christiansen JP, Klibanov A, et al. Influence of microbubble surface charge on capillary transit and myocardial contrast enhancement. J Am Coll Cardiol. 2002;40:811-819. (Pubitemid 34925631)
15. Klibanov AL. Microbubble contrast agents-targeted ultrasound imaging and ultrasound-assisted drug delivery applications. Invest Radiol. 2006;41:354-362. (Pubitemid 44406198)
16. De Jong N, Emmer M, van Wamel A, et al. Ultrasonic characterization of ultrasound contrast agents. Med Biol Eng Comput. 2009;47:861-873.
17. Schneider M. Characteristics of SonoVue. Echocardiography. 1999;16:743-746.
18. Handbook of Pharmaceutical Excipients. American Pharmaceutical Association, ed. Washington DC; American Pharmaceutical Association; 1986:209-213.
19. Ostensen J, Hede R, Myreng Y, et al. Intravenous injection of Albunex microspheres causes thromboxane mediated pulmonary hypertension in pigs but not in monkeys or rabbits. Acta Physiol Scand. 1992;144:307-315.
20. Grauer SE, Pantely GA, Xu J, et al. Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent: experimental studies in pigs. Am Heart J. 1996;132:938-945. (Pubitemid 26372748)
21. Schneider M. SonoVue a new ultrasound contrast agent. Eur Radiol. 1999; 9(suppl 3):S347-S348.
22. Toft KG, Hustvedt SO, Hals PA, et al. Disposition of perfluorobutane in rats after intravenous injection of Sonazoid. Ultrasound Med Biol. 2006;32:107-114. (Pubitemid 41814866)
23. Bzyl J, Lederle W, Rix A, et al. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38). European J Radiol. 2011 May 12. [Epub ahead of print.]
24. Rakhit DJ, Becher H, Monaghan M, et al. The clinical applications of myocardial contrast echocardiography. Eur J Echocardiography. 2007;8: 524-529.
25. Nesser HJ, Morcerf F, Teupe C, et al. Myocardial perfusion imaging using contrast echocardiography. Herz. 2002;27:217-226. (Pubitemid 34546859)
26. Albrecht T, Blomley M, Bolondi L, et al. Guidelines for the use of contrast agents in ultrasound. Ultraschall Med. 2004;25:249-256. (Pubitemid 39128145)
27. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS)-update 2008. Ultraschall Med. 2008;29:28-44.
28. Owen DR, Shalhoub J, Miller S, et al. Inflammation within carotid atherosclerotic plaque: assessment with late-phase contrast-enhanced US. Radiology. 2010;255: 638-644.
29. Zhao H, Xu R, Ouyang Q, et al. Contrast-enhanced ultrasound is helpful in the differentiation of malignant and benign breast lesions. Eur J Radiol. 2010;73:288-293.
30. Migaleddu V, Quaia E, Scanu D, et al. Imaging diagnosis of Crohn disease. Recenti Prog Med. 2010;101:185-193.
31. Mouterde G, Carotti M, d'Agostino MA. Contrast-enhanced ultrasound in musculoskeletal diseases [in French]. J Radiol. 2009;90(1 part 2):148-155.